Sai Life Sciences Ltd. (SAILIFE) fundamentals
Sai Life Sciences Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SAILIFE (ISIN INE570L01029). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sai Life Sciences Ltd. does
Sai Life Sciences Limited is an India-based contract research, development, and manufacturing organization (CRO/CDMO). The Company carries out contract research and manufacturing activities for customers engaged in pharmaceutical and biotechnology industries. It is engaged in offering a range of services tailor-made to the customer's requirements. It provides discovery and chemistry, manufacturing, and controls (CMC) services that span from drug discovery to process development and early-phase supplies, all the way to commercial launch and life cycle management. Its services include Integrated Drug Discovery, Synthetic & medicinal chemistry, Biology, drug metabolism and pharmacokinetics (DMPK), Genotoxicity, General Toxicology and Computational chemistry. Its CMC services include route scouting; process development; analytical development; process safety; stability studies; early and mid-phase supplies; late phase, commercial manufacturing; technology transfer, and technologies.
Valuation and market data
| Last close | ₹1585.00 |
|---|---|
| Market capitalisation | ₹30,539 crore |
| Enterprise value | ₹30,756 crore |
| P/E (TTM) | 0.00 |
| Price to book | 14.35 |
| Price to sales (TTM) | 13.32 |
| Book value per share | ₹110.46 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Dec 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,202 crore | ₹456 crore | ₹341 crore | 0.00 |
| Mar 2025 | ₹1,679 crore | ₹232 crore | ₹173 crore | 9.00 |
| Mar 2024 | ₹1,448 crore | ₹129 crore | ₹95 crore | 5.26 |
| Mar 2023 | ₹1,185 crore | ₹33 crore | ₹24 crore | 13.42 |
| Mar 2022 | ₹869 crore | ₹22 crore | ₹16 crore | 8.97 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 34.5% |
|---|---|
| Foreign institutions (FII) | 19.6% |
| Mutual funds | 29.5% |
| Other domestic institutions | 3.2% |
| Retail and others | 13.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.